MMP-2, TIMP-1, E-cadherin, and β-catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium

References

• Monaghan H, MacWhinnie N, Williams ARW. The role of matrix metalloproteinases-2, -7, and -9 and β-catenin in high grade endometrial carcinoma. Histopathology. 2007; 50: 348–57
   PubMed Web of Science ®Google Scholar
• Burton JL, Wells M. Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium. Histopathology. 1998; 33: 297–308
   PubMed Web of Science ®Google Scholar
• Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: A distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol. 1995; 26: 1260–7
   PubMed Web of Science ®Google Scholar
• Hui P, Kelly M, O'Malley DM, Tavassoli F, Schwartz PE. Minimal uterine serous carcinoma: A clinicopathological study of 40 cases. Mod Pathol. 2005; 18: 75–82
   PubMed Web of Science ®Google Scholar
• Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA. Molecular aspects of tumor cell invasion and metastasis. Cancer. 1993; 71: 1368–83
   PubMed Web of Science ®Google Scholar
• Chang C, Werb Z. The many faces of metalloproteinases: Cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol. 2001; 11: S37–S43
   PubMed Web of Science ®Google Scholar
• Di Nezza LA, Misajon A, Zhang J, Jobling T, Quinn MA, Ostor AG, et al. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer. 2002; 94: 1466–75
   PubMed Web of Science ®Google Scholar
• Graesslin O, Cortez A, Uzan C, Birembaut P, Quereux C, Darai E. Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions. Int J Gynecol Cancer. 2006; 16: 1911–7
   PubMed Web of Science ®Google Scholar
• Hinck L, Nathke IS, Papkoff J, Nelson WJ. Dynamics of cadherin/catenin complex formation: Novel protein interactions and pathways of complex assembly. J Cell Biol. 1994; 125: 1327–40
   PubMed Web of Science ®Google Scholar
• Shiozaki H, Tahara H, Oka H, Miyata M, Kobayashi K, Tamura S, et al. Expression of immunoreactive E–cadherin adhesion molecules in human cancers. Am J Pathol. 1991; 139: 17–23
   PubMed Web of Science ®Google Scholar
• Moreno-Bueno G, Hardisson D, Sarrio D, Sanchez C, Cassia R, Prat J, et al. Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol. 2003; 199: 471–8
   PubMed Web of Science ®Google Scholar
• Schlosshauer PW, Ellenson LH., Soslow RA. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Mod Pathol. 2002; 15: 1032–7
   PubMed Web of Science ®Google Scholar
• Mell LK, Meyer JJ, Tretiakova M, Khramtsov A, Gong C, Yamada SD, et al. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res. 2004; 10: 5546–53
   PubMed Web of Science ®Google Scholar
• Scholten AN, Aliredjo R, Creutzberg CL, Smit VTHBM. Combined E-cadherin, β-catenin, and β-catenin expression is a favorable prognostic factor in endometrial carcinoma. Int J Gynecol Cancer. 2006; 16: 1379–85
   PubMed Web of Science ®Google Scholar
• Holcomb K, Delatorre R, Pedemonte B, McLeod C, Anderson L, Chambers J. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. Obstet Gynecol. 2002; 100: 1290–5
   PubMed Web of Science ®Google Scholar
• Demopoulos RI, Mesia AF, Mittal K, Vamvakas E. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: Clues to pathogenesis. Int J Gynecol Pathol. 1999; 18: 233–7
   PubMed Web of Science ®Google Scholar
• Athanassiadou P, Athanassiades P, Grapsa D, Gonidi M, Athanassiadou AM, Stamati PN, et al. The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study. Int J Gynecol Cancer. 2007; 17: 697–704
   PubMed Web of Science ®Google Scholar
• Darvishian F, Hummer AJ, Thaler HT, Bhargava R, Linkov I, Asher M, et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: A clinicopathologic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol. 2004; 28: 1568–78
   PubMed Web of Science ®Google Scholar
• Iurlaro M, Loverro G, Vacca A, Cormio G, Ribatti D, Minischetti M, et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma. Eur J Clin Invest. 1999; 29: 793–801
   PubMed Web of Science ®Google Scholar
• Soini Y, Alarakkola E, Autio-Harmainen H. Expression of messenger RNAs for metalloproteinases 2 and 9, type IV collagen, and laminin in nonneoplastic and neoplastic endometrium. Hum Pathol. 1997; 28: 220–6
   PubMed Web of Science ®Google Scholar
• Graesslin O, Cortez A, Fauvet R, Lorenzato M, Birembaut P, Darai E. Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: A clinical-pathological correlation study. Ann Oncol. 2006; 17: 637–45
   PubMed Web of Science ®Google Scholar
• Nei H, Saito T, Yamasaki H, Mizumoto H, Ito E, Kudo R. Nuclear localization of β-catenin in normal and carcinogenic endometrium. Mol Carcinog. 1999; 25: 207–18
   PubMed Web of Science ®Google Scholar
• Behrens J, Von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature. 1996; 382: 638–42
   PubMed Web of Science ®Google Scholar
• Scholten AN, Creutzberg CL, van den Broek LJCM, Noordijk EM, Smit VTHBM. Nuclear β-catenin is a molecular feature of type I endometrial carcinoma. J Pathol. 2003; 201: 460–5
   PubMed Web of Science ®Google Scholar